“The third quarter was highlighted by positive interim data from the INTEGRIS-PSC trial of bexotegrast demonstrating a favorable safety profile and encouraging antifibrotic activity in PSC. Coupled with positive data reported from INTEGRIS-IPF, these data illustrate the broad potential of bexotegrast in fibrotic diseases across multiple organ systems,” said Bernard Coulie, president and CEO of Pliant Therapeutics. “Our pipeline continues to advance, led by the ongoing enrollment of our Phase 2b BEACON-IPF trial. We have also taken active steps to strengthen our leadership team with the appointments of Minnie Kuo as Chief Development Officer and Mishima Gerhart as Chief Regulatory Officer, coming at an important time in Pliant’s evolution into a late-stage clinical development company.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PLRX:
- Pliant Therapeutics presents three posters on PLN-101095
- Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
- Pliant Therapeutics to highlight Phase 2a interim data on bexotegrast
- Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
- Pliant Therapeutics to participate in a conference call with JPMorgan